ED-Finanzas

No es posible guardar favoritos sin iniciar sesión.

Usá Login / Registrar en el header (usuario + contraseña).

EYPT

EyePoint Inc · NASD

Healthcare · Biotechnology · USA · Small

4.87
-9.88 (-66.98%)
Aug 17 3:59 PM ET

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Chart

Lightweight Charts · Yahoo Finance

Date Headline URL From
Aug-17-26 11:00PM Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today? link (Stocktwits)
Aug-17-26 07:51PM OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why link (Stocktwits)
Aug-17-26 11:14AM EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. link (Barrons.com)
Aug-17-26 10:56AM EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden link (InvestorsHub)
Aug-17-26 09:41AM The Surprising Reason EyePoint Just Crashed 69% link (Investor's Business Daily)
Aug-17-26 09:19AM EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback Retail Sees Ocular Therapeutics As A Better Buyout Candidate link (Stocktwits)
Aug-17-26 07:00AM EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD link (GlobeNewswire)
Aug-14-26 04:32PM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Aug-05-26 07:33AM EyePoint: Q2 Earnings Snapshot link (Associated Press)
Aug-05-26 07:00AM EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Jul-30-26 07:00AM EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) link (GlobeNewswire)
Jul-16-26 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Jul-13-26 07:00AM EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer link (GlobeNewswire)
Jun-16-26 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
May-19-26 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)
May-18-26 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
May-14-26 07:00AM EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data link (GlobeNewswire)
May-07-26 08:30AM EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary link (Moby)
May-06-26 07:21AM EyePoint: Q1 Earnings Snapshot link (Associated Press)
May-06-26 07:00AM EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Apr-29-26 07:00AM EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 link (GlobeNewswire)
Apr-16-26 04:01PM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Mar-20-26 06:12PM EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug link (Reuters)
Mar-16-26 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Mar-04-26 04:03PM EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... link (GuruFocus.com)
Mar-04-26 12:36PM EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary link (Moby)
Mar-04-26 10:36AM Eyepoint Pharmaceuticals Q4 Earnings Call Highlights link (MarketBeat)
Mar-04-26 08:20AM EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates link (Zacks)
Mar-04-26 07:23AM EyePoint: Q4 Earnings Snapshot link (Associated Press Finance)
Mar-04-26 07:00AM EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Mar-02-26 07:00AM EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema link (GlobeNewswire)
Feb-26-26 12:15PM Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates link (Zacks)
Feb-25-26 07:00AM EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 link (GlobeNewswire)
Feb-24-26 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)
Feb-18-26 07:58AM EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? link (Zacks)
Feb-18-26 07:00AM EyePoint Appoints Michael Campbell as Chief Commercial Officer link (GlobeNewswire)
Feb-17-26 08:30AM Ocular Therapeutix stock news: Why positive data led to a 25% drop link (Investing.com)
Feb-17-26 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Feb-16-26 09:40AM Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year link (24/7 Wall St.)
Feb-13-26 05:12PM EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program link (MarketBeat)
Feb-05-26 07:00AM EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 link (GlobeNewswire)
Jan-16-26 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Jan-07-26 07:00AM EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 link (GlobeNewswire)
Dec-22-25 12:00PM EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know link (Zacks)
Dec-22-25 08:10AM 3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 link (Zacks)
Dec-20-25 12:00PM The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside link (Barchart)
Dec-17-25 07:00AM EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference link (GlobeNewswire)
Dec-16-25 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Nov-19-25 07:00AM EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration link (GlobeNewswire)
Nov-17-25 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Nov-07-25 04:00AM EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... link (GuruFocus.com)
Nov-05-25 08:15AM EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates link (Zacks)
Nov-05-25 07:22AM EyePoint Pharmaceuticals: Q3 Earnings Snapshot link (Associated Press Finance)
Nov-05-25 07:00AM EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Nov-04-25 08:06AM EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect link (GuruFocus.com)
Nov-03-25 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)
Oct-29-25 07:00AM EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 link (GlobeNewswire)
Oct-16-25 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Oct-14-25 10:43PM EyePoint Announces Pricing of Public Offering link (GlobeNewswire)
Oct-14-25 04:35PM EyePoint Announces Proposed Public Offering of Common Stock link (GlobeNewswire)
Oct-14-25 04:01PM EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema link (GlobeNewswire)
Sep-25-25 09:29AM Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? link (Zacks)
Sep-23-25 01:13PM Biotech Stocks Rally. 3 Favorite Plays From the Charts. link (Barrons.com)
Sep-16-25 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Aug-26-25 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)
Aug-18-25 04:01PM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Aug-06-25 08:30AM EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates link (Zacks)
Aug-06-25 07:30AM EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference link (GlobeNewswire)
Aug-06-25 07:26AM EyePoint Pharmaceuticals: Q2 Earnings Snapshot link (Associated Press Finance)
Aug-06-25 07:00AM EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Aug-05-25 10:08AM EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect link (GuruFocus.com)
Jul-30-25 06:00PM Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates link (Zacks)
Jul-30-25 07:00AM EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 link (GlobeNewswire)
Jul-30-25 05:57AM Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD link (Clinical Trials Arena)
Jul-29-25 07:00AM EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration link (GlobeNewswire)
Jul-16-25 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Jun-16-25 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Jun-06-25 11:54AM Breakout Momentum Plays You May Not Know About link (MarketBeat)
May-28-25 04:01PM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)
May-27-25 07:00AM EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration link (GlobeNewswire)
May-16-25 07:00AM EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
May-13-25 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)
May-07-25 02:49PM Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum link (Seeking Alpha)
May-07-25 02:49PM EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript link (Seeking Alpha)
May-07-25 09:30AM EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say link (Zacks)
May-07-25 08:25AM EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates link (Zacks)
May-07-25 07:22AM EyePoint Pharmaceuticals: Q1 Earnings Snapshot link (Associated Press Finance)
May-07-25 07:00AM EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Apr-30-25 07:00AM EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 link (GlobeNewswire)
Apr-16-25 07:00AM EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Mar-27-25 07:00AM EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference link (GlobeNewswire)
Mar-17-25 07:00AM EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) link (GlobeNewswire)
Mar-06-25 02:14AM Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call link (Thomson Reuters StreetEvents)
Mar-06-25 02:06AM EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... link (GuruFocus.com)
Mar-05-25 09:30AM EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say link (Zacks)
Mar-05-25 08:25AM EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates link (Zacks)
Mar-05-25 07:34AM EyePoint Pharmaceuticals: Q4 Earnings Snapshot link (Associated Press Finance)
Mar-05-25 07:00AM EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments link (GlobeNewswire)
Mar-04-25 07:17AM Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result link (GuruFocus.com)
Mar-04-25 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences link (GlobeNewswire)